Shows
Proactive - Interviews for investorsSolvonis CEO says Awakn shareholder approval of acquisition is a 'great endorsement'Solvonis Therapeutics PLC CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the proposed acquisition of Awakn Life Sciences following strong shareholder approval. Over 99% of Awakn’s shareholders voted in favour of the transaction, which Tennyson described as a “great endorsement” of the strategic fit and potential of combining the two companies.
Solvonis is acquiring Awakn for around £5 million in an all-stock transaction. The deal includes two key clinical-stage programs. The lead candidate, AWKN-001, targets severe AUD in the UK and EU markets. It is currently in phase three trials. According to Tennyson, “People coming on to that trial were sober sev...2025-04-2306 minProactive - Interviews for investorsSolvonis Therapeutics engages PharmaVentures to support key AUD assetsSolvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002.
PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.”
The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second q...2025-04-0405 min
PharmaVenturesThe Future of Diagnostics and the Impact on DealsListen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss:
Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing
Its application to specific medical models and therapy areas – including personalised medicine, oncology, and Alzheimer’s
Key players in the area, and their commercial models
The importance of diagnostics working hand-in-hand with therapeutics
Licensing and M&A transactions, and the potential deal values in the future
To find out what the diagnostics deal making landscape looks like for y...2023-11-2924 minPharmaVenturesThe Involvement of Law and Tax in Deal MakingListen as Colin McCall, Partner - Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process. They discuss a range of topics where different advisors use their expertise to help you achieve the best deal and avoid pitfalls in the future:
The deal stages when expert advice can save you time and money.
5 key areas relating to tax in a licensing deal, and the risk of a “dry tax charge”.
The importance of obtai...2023-10-2528 minPharmaVenturesCommercial Due Diligence and the Deal Making ProcessOnce you have identified an asset you want to acquire or partner, what happens next?
In this podcast, Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.
Ralph talks to Adrian Dawkes about the different components involved in pre- and full- commercial due diligence:
- Understanding KOLs and payer perspectives to help you define market positioning and pricing.
- Gettin...2023-09-2720 minPharmaVenturesFinancial and Technical Aspects Driving Today’s Life Sciences Deal MakingListen as Andrew Guise gives key insight into the deal making landscape - asset value, accessing the market, positioning and the actual deal process in the current economic climate - from the unique position standing astride both the financial world and the technical world translating science into value.
About the Interviewee:
Andrew Guise is a Managing Director at PharmaVentures and is a member of the Corporate Advisory Team.
Andrew is a highly accomplished executive with a wealth of experience in finance, business development, and leadership. Notable deals including IPOs for I...2023-08-3034 minPharmaVenturesCurrent Challenges for CROs and CDMOs in Drug Development and SupplyListen as Jansen Jacob, Frank Dollard and Steve Garland discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice; how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are trying to squeeze costs to meet the needs of a larger proportion of people requiring more medicines.
About the Interviewees:
Jansen Jacob is a Vice President at PharmaVentures.
Jansen is a healthcare tra...2023-07-2641 minPharmaVentures4 Common Mistakes in PartneringListen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.
Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right price.
About the Interviewee:
Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.
Ov...2023-06-2820 minPharmaVenturesThe Importance of Pricing and Market Access in Licensing, Partnering and Early-Stage DevelopmentListen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.
Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies.
Understanding payer perspectives can help you define market positioning and pricing.
Targeting drug development at payers, as well as the regulators, can ensure adoption.
Payers can become advocates, not blockers, given the right data and narrative.
How combining pricing and market access with valuation work can...2023-05-1733 minPharmaVenturesMedical Device and In Vitro Diagnostic Regulations are changing. How will you be affected?Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK:
Can existing products continue to be sold?
What will global manufacturers need to do?
What is the impact for companion diagnostics being used alongside drugs in clinical trials?
How is the environment in Great Britain different, and what does this mean for innovators?
What’s the impact for patients?
A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.
2023-04-2528 minPharmaVenturesThe Korean Partnering Opportunity for Western Biopharmaceutical CompaniesListen as JungHyun Eom describes the Korean partnering opportunity for western biopharma companies and her exciting new role establishing PharmaVentures’ office in Seoul to support current and prospective clients in the wider APAC region, serving as the bridge between the innovation in Asia and its commercialisation to the rest of the world. Hosted by Adrian Dawkes.
2023-04-0330 min
PharmaVenturesHow to Acquire Companies or Assets SuccessfullyIn this podcast, PharmaVentures’ deal experts discuss the process of helping clients in the life sciences industry acquire or license assets or rights in specific markets or whole companies. Hosted by Adrian Dawkes.
2023-02-2419 minPharmaVenturesRobust Valuations of Life Science Companies, Assets and Licensing DealsListen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience combines with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals to give their clients the confidence to negotiate the most robust and defensible positions in deal making to secure the most impactful financial terms.
2023-02-2337 minPharmaVenturesReview of 2022: M&A, Licensing and FundraisingListen as Fintan Walton, PharmaVentures’ CEO and Founder, reflects on this year’s deal trends in M&A, Licensing and Fundraising, considers the significant macroeconomic events, and offers insight into what impact they may have on the global pharma and biotech industry in 2023. Hosted by Adrian Dawkes.
2023-02-2325 min
PharmaVenturesThe Role of CDMOs in a Fast Evolving Manufacturing LandscapeListen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine. Hosted by Adrian Dawkes.
2023-02-2342 min
PharmaVenturesHow Your Pricing and Reimbursement Strategy Affects Your Deal Making SuccessListen as PharmaVentures’ Pricing and Market Access expert, Ralph Hughes, recommends elements of a robust plan to help you achieve the best pricing and market access for your drug, and to give you the increased confidence to strengthen your position during deal making negotiations. Hosted by Adrian Dawkes.
2022-11-0923 min
CPhI Podcast SeriesSuccess in healthcare M&A: Taking a people-first approachGlobal mergers and acquisitions hit an all-time high in 2021, and in the life sciences industry these kinds of deals show no sign of slowing down. Many companies are turning to M&A to optimise their portfolios and gain access to new technologies, fuelled by an abundance of capital in the sector. These deals can have transformative effects on the companies involved; ideally promoting synergy, diversifying product offerings and improving economies of scale. However, striking a successful deal takes a lot more than agreeing a price and signing on the dotted line. A company must consider the i...2022-04-1317 min